25. (Replacing claim 2) A sustained-release pharmaceutical dosage form according to claim 24 wherein the weight ratio between the mizolastine and the organic acid is between 0.3 and 1. 26.

26. (Replacing amended claim 3) A sustained-release pharmaceutical dosage form according to claim 24 wherein the fatty matrix is a member selected from the group consisting of hydrogenated castor oil, a hydrogenated lecithin, a long-chain fatty acid and a triglyceride esterified with one, two or three medium-chain fatty acids.

B' cont

27. (Replacing amended claim 4) A sustained-release pharmaceutical dosage form according to claim 24 wherein the organic acid is a member selected from the group consisting of maleic, tartaric, malic, fumaric, lactic, citric, adipic and succinic acid in the form of a racemate or an isomer.

28. (Replacing claim 5) A sustained-release pharmaceutical dosage form according to claim 24 wherein the organic acid is L-tartaric acid.

Sub D'

29. (Replacing claim 6) A sustained-release pharmaceutical dosage form according to claim 24 wherein the ratio between the mizolastine and the L-tartaric acid is 0.5.

30. (Replacing claim 7) A sustained-release pharmaceutical dosage form according to claim 24 which contains from 1 to 25 mg of mizolastine.

31. (Replacing claim 8) A coated sustained-release tablet having:

a) a core comprising mizolastine, a fatty matrix and an organic acid; and

b) a dissolution profile which is pH independent.

32. (Replacing claim 9) A sustained-release tablet of claim 31 wherein the dissolution profile is one in which about 30 to 70% of the mizolastine is dissolved in 1 hour and 100% of the mizolastine is dissolved in 3 to 5 hours.

33. (Replacing claim 10) A sustained-release tablet of claim 31 wherein the weight ratio between the mizolastine and the organic acid is between 0.3 and 1.

34. (Replacing claim 11) A sustained-release tablet of claim 31 wherein the fatty matrix is a member selected from the group consisting of hydrogenated castor oil, a hydrogenated lecithin, a long-chain fatty acid and a triglyceride esterified with one, two or three medium-chain fatty acids.

35. (Replacing claim 12) A sustained-release tablet of claim 31 wherein the organic acid is a member selected from the group consisting of maleic, tartaric, malic, fumaric, lactic, citric, adipic and succinic acid in the form of a racemate or an isomer.

36. (Replacing claim 13) A sustained-release tablet of claim 31 wherein the organic acid is L-tartaric acid.

37. (Replacing claim 14) A sustained-release tablet of claim 36 wherein the ratio between the mizolastine and the L-tartaric acid is 0.5.

38. (Replacing claim 15) A sustained-release tablet of claim 31 wherein the core contains from 1 to 25 mg of mizolastine.

39. (Replacing claim 16) A sustained-release tablet of claim 31 wherein the organic acid has a pK of 2 or more.

40. (Replacing claim 17) A coated sustained-release tablet containing from 1 to 25 mg of mizolastine, a fatty matrix and L-tartaric acid, the weight ratio between the mizolastine and the L-tartaric acid is between 0.3 and 1.

B'cont

41. (Replacing claim 18) A coated sustained-release tablet of claim 40, wherein the ratio between the mizolastine and the L-tartaric acid is 0.5.

42. (Replacing claim 19) A coated sustained-release tablet of claim 41, wherein the fatty matrix is hydrogenated castor oil.

43. (Replacing claim 20) A coated sustained-release tablet of claim 42, wherein the tablet has a dissolution profile which is independent of pH and is one in which about 50% of the mizolastine is dissolved in 1 hour and 100% of the mizolastine is dissolved in 3 to 5 hours.--